AI Article Synopsis
- Asthma is a complicated disease that doctors don’t fully understand yet, and patients can be grouped based on their symptoms and underlying causes.
- Recently, asthma patients have been divided into two main types: type 2 and non-type 2 asthma, but this might be too simple.
- The review talks about finding specific traits in asthma patients that can help create new medicines, aiming to discover new patient groups and treatments.
Article Abstract
Asthma is a complex, heterogeneous disease in which the underlying mechanisms are not fully understood. Patients are often grouped into phenotypes (based on clinical, biologic, and physiologic characteristics) and endotypes (based on distinct genetic or molecular mechanisms). Recently, patients with asthma have been broadly split into 2 phenotypes based on their levels of type 2 inflammation: type 2 and non-type 2 asthma. However, this approach is likely oversimplified, and our understanding of the non-type 2 mechanisms in asthma remains extremely limited. A better understanding of asthma phenotypes and endotypes may assist in development of drugs for new therapeutic targets in asthma. One approach is to identify "treatable traits," which are specific patient characteristics related to phenotypes and endotypes that can be targeted by therapies. This review will focus on emerging treatable traits in asthma and aim to describe novel patient subgroups and endotypes that may represent the next step in the search for new therapeutic approaches.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509971 | PMC |
| http://dx.doi.org/10.1016/j.jacig.2022.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.
Patient Prefer Adherence
January 2025
Respiratory Research@Alfred, Monash University, Melbourne, VIC, Australia.
Purpose: Oral corticosteroids (OCS) are an effective treatment for severe uncontrolled asthma or asthma exacerbations, but frequent bursts or long-term use carry serious and sometimes irreversible adverse effects, or complications such as adrenal insufficiency upon discontinuation. Our aim was to survey people with asthma on their experiences of, and attitudes towards, using OCS.
Patients And Methods: This study was a national descriptive cross-sectional survey of people with asthma in Australia.
Beyond bronchial thermoplasty - where to now?
EClinicalMedicine
January 2025
Department of Mathematics, University of Auckland, Auckland, New Zealand.
With the impending 'retirement' of bronchial thermoplasty (BT) for the treatment of patients with asthma, there is much to learn from this real-world experiment that will help us develop more effective future therapies with the same primary target i.e., airway smooth muscle (ASM) remodelling.
View Article and Find Full Text PDFReal-world Management of COPD: Dupilumab's Role in Targeting T2 Inflammation as a Treatable Trait.
Arch Bronconeumol
January 2025
Pulmonology Department, 12th of October University Hospital, 28041 Madrid, Spain.
Towards the integrated care of COPD, asthma and bronchiectasis: description and objectives of a treatable trait-based complex obstructive airway disease unit.
Expert Rev Respir Med
January 2025
Department of Respiratory MedicineComplex Obstructive Airway Disease Unit, Hospital Universitario Son Espases-IdISBa-CIBERES Palma de Mallorca Spain.
Introduction: Expert management of Complex Obstructive Airway Diseases (COAD) requires knowledge, resources and skills that are commonly shared in the management of the different conditions usually included in the acronym, namely asthma, bronchiectasis and Chronic Obstructive Pulmonary Disease (COPD). We discuss the basis to shift the paradigm of single-disease management into a holistic approach and describe its potential benefits.
Areas Covered: The prevalence and significance of the overlap between the different conditions is reviewed.
Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?
Pulm Ther
January 2025
MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!